This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

Chimeric antigen receptor T cell therapy reduces vaccine immunity, with many patients lacking seroprotection despite stable antibody levels.

T-cell therapy is the most efficacious approach for many patients with relapsed/refractory multiple myeloma, but it currently comes with 2 periods ...

Researchers are advancing CAR T-cell therapy for solid tumors using armored cells that deliver IL-36γ. Expanded manufacturing ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.

Myeloma is a cancer that affects specialised antibody-producing cells called plasma cells. Over your lifetime, your body ...

In recent years, CAR T-cell therapy has become a revolutionary, if risky, treatment for some late-stage cancers. Yet CAR T ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...